TAMs and PD-1 Networking in Gastric Cancer: A Review of the Literature

TAMs and PD-1 Networking in Gastric Cancer: A Review of the Literature

Background: Gastric cancer (GC) is one of the most common and aggressive types of cancer. Immune checkpoint inhibitors (ICIs) have proven effective in treating various types of cancer. The use of ICIs in GC patients is currently an area of ongoing research. The tumor microenvironment (TME) also seem...

Full description

Bibliographic Details
Main Authors:	Melina Yerolatsite, Nanteznta Torounidou, Aristeidis Gogadis, Fani Kapoulitsa, Panagiotis Ntellas, Evangeli Lampri, Maria Tolia, Anna Batistatou, Konstantinos Katsanos, Davide Mauri
Format:	Article
Language:	English
Published:	MDPI AG 2023-12-01
Series:	Cancers
Subjects:	tumor microenvironment (TME) tumor-associated macrophages (TAMs) immune checkpoint inhibitors (ICIs) PD-1/PD-L1 gastric cancer
Online Access:	https://www.mdpi.com/2072-6694/16/1/196

Similar Items

Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy
by: Melina Yerolatsite, et al.
Published: (2024-03-01)

DNA Damage Repair in Brain Tumor Immunotherapy
by: Shihong Zhao, et al.
Published: (2022-01-01)

Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
by: Yunzhou Pu, et al.
Published: (2022-05-01)

The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication
by: Shengjin Dou, et al.
Published: (2021-09-01)

Immune microenvironment and therapeutic progress of recurrent hepatocellular carcinoma after liver transplantation
by: Xin Jin, et al.
Published: (2023-02-01)

Defining Tumor Microenvironment as a Possible Target for Effective GEP-NENs Immunotherapy—A Systematic Review
by: Paulina Chmiel, et al.
Published: (2023-10-01)

Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers
by: Raed Sulaiman, et al.
Published: (2023-07-01)

Advances in dendritic cell vaccination therapy of cancer
by: Sajad Najafi, et al.
Published: (2023-08-01)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
by: Rui Zhao, et al.
Published: (2021-01-01)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
by: Man Wang, et al.
Published: (2023-02-01)

Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy
by: Xinran Gao, et al.
Published: (2024-03-01)

Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
by: Victoria Foy, et al.
Published: (2023-09-01)

Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment
by: Genhao Zhang
Published: (2022-09-01)

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy
by: Sven H. Loosen, et al.
Published: (2021-03-01)

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
by: Rita Balsano, et al.
Published: (2023-03-01)

An oxidative stress biomarkers predict prognosis in gastric cancer patients receiving immune checkpoint inhibitor
by: Guiming Deng, et al.
Published: (2023-07-01)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
by: Hongjing Zang, et al.
Published: (2020-04-01)

Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment
by: Jingbo Zhang, et al.
Published: (2023-12-01)

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
by: Carlo Genova, et al.
Published: (2022-01-01)

TAM Receptor Inhibition–Implications for Cancer and the Immune System
by: Pia Aehnlich, et al.
Published: (2021-03-01)

Tumor‐associated macrophages (TAMs)‐derived osteopontin (OPN) upregulates PD‐L1 expression and predicts poor prognosis in non‐small cell lung cancer (NSCLC)
by: Yue Li, et al.
Published: (2021-10-01)

Lipid metabolic features of T cells in the Tumor Microenvironment
by: Wanshuang Lou, et al.
Published: (2022-10-01)

The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy
by: Bo Hou, et al.
Published: (2023-01-01)

Immune Evasion Mechanism and AXL
by: Hye-Youn Son, et al.
Published: (2021-10-01)

Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience
by: Paola Parente, et al.
Published: (2022-03-01)

Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
by: Ting Yan, et al.
Published: (2024-02-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy
by: Elnaz Rouzbahani, et al.
Published: (2022-12-01)

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer
by: Xin Zhang, et al.
Published: (2023-03-01)

Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer
by: Huihui Ji, et al.
Published: (2022-08-01)

PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread
by: Tiina Vesterinen, et al.
Published: (2019-08-01)

Editorial: New advancement in tumor microenvironment remodeling and cancer therapy
by: Yi Yao, et al.
Published: (2024-03-01)

نقش PD-1/ PD-L1 و Anti-PD-1/ PD-L1 در پیشرفت و سرکوب سرطان
by: نرگس عبدالهی, et al.
Published: (2023-11-01)

Gut microbiome modulates efficacy of immune checkpoint inhibitors
by: Ming Yi, et al.
Published: (2018-03-01)

Expression of PD-1 mitigates phagocytic activities TAM in osteosarcoma
by: Chenhong Zheng, et al.
Published: (2024-01-01)

Use of programmed cell death protein 1 (PD-1) inhibitor therapy in HIV-infected patients with advanced cancer: a single-center study from China
by: Luling Wu, et al.
Published: (2023-05-01)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
by: Yanting Zhou, et al.
Published: (2023-06-01)

Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor‐induced interstitial lung disease in patients with non‐small cell lung cancer
by: Daiki Murata, et al.
Published: (2023-01-01)

The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor
by: Charlotte Margareta Brinch, et al.
Published: (2022-11-01)

Mechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy
by: Yang Xicheng
Published: (2022-01-01)